Drugs for Neglected Diseases initiative and Pharco Pharmaceuticals to test affordable hepatitis C regimen with support of Malaysian and Thai governments

Posted in CRM Updates, In The News, News, Press Release

[The International Liver Congress 2016, Barcelona, Spain, 13 April 2016]

Potentially pan-genotypic combination of ravidasvir and sofosbuvir to be tested in Malaysia and Thailand with target price of under $300

The Drugs for Neglected Diseases initiative (DNDi) and the Egyptian drug manufacturer Pharco Pharmaceuticals have signed agreements covering the clinical testing and scale-up of a hepatitis C treatment regimen at a price of just under $300.
[Español] [Français] [Português]

“If our clinical trials are successful, this regimen could become part of a public health approach to treating hepatitis C that will be an alternative to today’s high drug prices and treatment rationing,” said Dr Bernard Pécoul, Executive Director of DNDi. “An affordable cure for this deadly disease that treats all strains, or ‘genotypes,’ of the disease, is essential to tackling the worldwide hepatitis C epidemic.”

• Continue Reading

Hepatitis C treatment at a fraction of the cost to be available soon

Posted in CRM Updates, In The News, Local, News

PETALING JAYA: Affordable Hepatitis C treatment will soon be available for patients once trials on generic drugs are completed.

The non-profit Drugs for Neglected Diseases initiative (DNDi), of which the Malaysian Health Ministry is a founding member, and Egyptian drug manufacturer Pharco Pharmaceuticals on Wednesday signed agreements covering clinical testing and scale-up of a Hepatitis C treatment regimen at a price of just under US$300 (RM1,166) at the International Liver Congress 2016 in Barcelona, Spain.

This is a fraction of the current US$40,000 treatment (RM155,442) using the original drug brand, according to a Health Ministry official.

• Continue Reading